Metotrexato Accord

Methotrexate, the active ingredient in Metotrexato Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable for intra‑arterial, intramuscular, and intrathecal use. It is employed in the treatment of certain cancers and autoimmune disorders in adult and pediatric patients.

GNH USA supplies Metotrexato Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Clients benefit from reliable logistics and responsive technical support throughout the supply chain.

Methotrexate is used in several oncologic and autoimmune disease pathways to inhibit abnormal cell proliferation. - Leukemia: reduces malignant leukocyte proliferation and improves remission rates. - Lymphoma: suppresses growth of malignant lymphoid cells, aiding disease control. - Rheumatoid arthritis: decreases inflammatory activity and joint damage in moderate to severe disease. - Psoriasis: limits rapid skin cell turnover, leading to lesion clearance.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring early in therapy. - Fatigue: persistent tiredness affecting daily activities. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic irritation detectable in labs.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis with prolonged use. - Pulmonary fibrosis: interstitial lung disease presenting with cough and dyspnea. - Bone marrow failure: pancytopenia leading to infection risk. - Renal impairment: decreased clearance causing drug accumulation.

Prior to initiating methotrexate therapy, several safety considerations should be evaluated. - Pregnancy: avoid use unless benefits outweigh risks; teratogenic potential exists. - Renal function: assess creatinine clearance and adjust dosing if impairment is present. - Liver function: monitor transaminases regularly to detect hepatotoxicity. - Hematologic status: perform baseline and periodic complete blood counts. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - NSAIDs: can reduce renal clearance and heighten toxicity. - Trimethoprim‑sulfamethoxazole: may cause severe bone marrow suppression. - Live vaccines: increased risk of serious infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Penicillins: may decrease methotrexate plasma levels, reducing effectiveness. - Proton pump inhibitors: can affect gastrointestinal absorption and increase systemic exposure.